Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Open access

Abstract

BACKGROUND: Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes. METHODS: We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: A total of 616 participants underwent randomization. The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001), and the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001). The results for the confirmatory secondary end points favored semaglutide over placebo (estimated between-group difference in change in 6-minute walk distance, 14.3 m [95% CI, 3.7 to 24.9; P = 0.008]; win ratio for hierarchical composite end point, 1.58 [95% CI, 1.29 to 1.94; P<0.001]; and estimated treatment ratio for change in CRP level, 0.67 [95% CI, 0.55 to 0.80; P<0.001]). Serious adverse events were reported in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group. CONCLUSIONS: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).

Overview

CoChat Summary

TL;DR

In the STEP-HFpEF DM trial, once-weekly semaglutide 2.4 mg improved heart failure–related symptoms and produced greater weight loss than placebo over 52 weeks in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. Confirmatory secondary end points (6-minute walk distance, a hierarchical composite, and CRP) also favored semaglutide.

Key findings

  • KCCQ-CSS mean change: 13.7 points with semaglutide vs 6.4 points with placebo (estimated difference 7.3 points; 95% CI 4.1 to 10.4; P<0.001).
  • Mean percentage change in body weight: −9.8% with semaglutide vs −3.4% with placebo (estimated difference −6.4 percentage points; 95% CI −7.6 to −5.2; P<0.001).
  • Confirmatory secondary end points favored semaglutide: 6-minute walk distance difference 14.3 m (95% CI 3.7 to 24.9; P=0.008); win ratio for the hierarchical composite 1.58 (95% CI 1.29 to 1.94; P<0.001); treatment ratio for CRP change 0.67 (95% CI 0.55 to 0.80; P<0.001).
  • Serious adverse events occurred in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group.

Methods

  • Randomized, placebo-controlled trial: 616 participants with HFpEF, BMI ≥30, and type 2 diabetes were assigned to once-weekly semaglutide 2.4 mg or placebo for 52 weeks.
  • Co-primary end points: change from baseline in KCCQ-CSS (0–100, higher = fewer symptoms/limitations) and change in body weight.
  • Confirmatory secondary end points: change in 6-minute walk distance; a hierarchical composite of death, heart failure events, and differences in KCCQ-CSS and 6-minute walk distance change; and change in CRP level. (Funded by Novo Nordisk; NCT04916470.)

Limitations

  • Not stated in the paper (the provided text is the abstract and bibliographic record; no limitations section is included).
  • Evident from the text: the report covers a 52-week treatment period only, so durability beyond 1 year is not addressed; and the trial population is restricted to patients with HFpEF, BMI ≥30, and type 2 diabetes, limiting generalizability to other HFpEF or non-diabetic populations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2313917

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 0 Not checked · 7 Own results and interpretations

  • It may state two separate claims as one. 2
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 35 references

Cited by

See all 758

Metadata

Authors
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., Jensen, T. J., Liisberg, K., Lindegaard, M. L., Abhayaratna, W., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ezekowitz, J. A., Fu, M., Ito, H., Lelonek, M., Melenovský, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., van der Meer, P., Von Lewinski, D., Wolf, D., & Shah, S. J.
Affiliations
  • University of Copenhagen (DK)
  • From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.), the Diabetes Research Centre, University of Leicester, and the NIHR Leicester Biomedical Research Centre, Leicester (M.J.D.), and the Division of Cardiovascular Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester (F.Z.A.) — all in the United Kingdom; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); the Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Novo Nordisk, Søborg (G.K.H., D.V.M., M.B.T., T.J.J., K.L., M.L.L.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine and Section on Geriatrics an...
Venue
New England Journal of Medicine
Published
2024-04-18
Volume
390
Issue
15
Pages
1394-1407
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4393255879
Cited by
758
References
35
Citations by year
2026: 282 · 2025: 345 · 2024: 131
FWCI
226.84
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
semaglutide, obesity, heart failure with preserved ejection fraction, type 2 diabetes, GLP-1 receptor agonists, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, heart failure events, body mass index, symptom burden, adverse events, drug safety
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. https://app.cochat.ai/papers/10.1056/nejmoa2313917
The paper
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., Jensen, T. J., Liisberg, K., Lindegaard, M. L., Abhayaratna, W., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ezekowitz, J. A., Fu, M., . . . Shah, S. J. (2024). Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2313917

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.